Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 1443436-80-3 spphpspafspafdnlyywdq in China, also supports custom service. Welcome to wholesale bulk high quality cas 1443436-80-3 spphpspafspafdnlyywdq from our factory. Contact us for more details.
| Description | The 20-mer SPPHPSPAFSPAFDNLYYWDQ, used for long-peptide epitope mapping, MHC cross-presentation and T-cell assays; Pro/Ser-rich for recognition and long-peptide vaccine studies. |
Product Basic Information Table
| Product Standard English Name | Product Abbreviation / Alias | Function Tags (comma-separated) | Core Structure | Molecular Formula | Exact Mass (Da) | Average MW (Da) | Salt Form | Length (aa) |
| SPPHPSPAFSPAFDNLYYWDQ (Rat HER2/neu p1209 MHC-II CD4 T-Helper Epitope Peptide; CAS 1443436-80-3) | SPPHPSPAFSPAFDNLYYWDQ; rat HER2/neu p1209; PEP-SPPH21-01 | HER2/neu epitope peptide, MHC-II CD4 Th epitope, dendritic-cell vaccine, breast-cancer model, Th1 anti-tumor immunity, anti-PD-1 combination, Tyr x2/Trp x1 light-sensitive, DMSO-assisted | Linear 21-mer, H-Ser-Pro-Pro-His-Pro-Ser-Pro-Ala-Phe-Ser-Pro-Ala-Phe-Asp-Asn-Leu-Tyr-Tyr-Trp-Asp-Gln-OH (SPPHPSPAFSPAFDNLYYWDQ), free acid (C-terminal -COOH); MHC-II CD4+ T-helper epitope from rat HER2/neu (erbB2) p1209 segment; contains Tyr x2, Trp x1, no Cys/Met | C116H150N26O33 | 2435.09 | 2436.62 | Not specified (typical TFA salt for synthetic peptides; per COA) | 21 |
Physicochemical Solubility & Storage Parameters
| Product Code | Appearance | Long-term Storage | Short-term Storage | Solution Stability | Solid Powder Stability |
| PEP-SPPH21-01 | White to off-white powder (synthetic linear 21-mer containing 2 Tyr and 1 Trp; typical TFA salt form) | Store at -20°C, sealed, desiccated and light-protected (amber vial/aluminum foil), ~2 years; contains Tyr x2 and Trp x1 which readily photo-oxidize, so keep strictly light-protected and away from oxidants; aliquot and avoid repeated freeze-thaw. | 2-8°C, light-protected, for ~1-2 weeks; working aliquots at -20°C, light-protected; prepare fresh and avoid freeze-thaw and light exposure. | Intermediate-to-high hydrophobicity (rich in Ser/Pro/Ala/Phe plus aromatic Tyr x2 and Trp x1); poor water solubility - first dissolve completely in a small volume of DMSO, then dilute stepwise with sterile water or pH 7.4 PBS/culture medium to target concentration (keep final DMSO <=10%). Solutions are light-sensitive: use at 4°C within ~1 week, store aliquoted at -20°C light-protected ~1-3 months; avoid repeated freeze-thaw and light to prevent Trp/Tyr oxidation. | No Cys/Met; but contains light-sensitive Trp/Tyr, so solid is stable ~2 years at -20°C, dry and light-protected. If shipped as a TFA salt it is hygroscopic: weigh quickly, reseal with desiccant and keep light-protected. |
Functional Description
| Product Code | Frontend Short Summary | Detailed Biological Function Description | Applicable Research Areas (comma-separated) | Targets / Pathways |
| PEP-SPPH21-01 | A 21-mer MHC-II CD4+ T-helper epitope from the rat HER2/neu p1209 segment (SPPHPSPAFSPAFDNLYYWDQ), for HER2-DC dendritic-cell vaccines, CD4 Th1 anti-tumor immunity in breast-cancer models, and sequential combination with anti-PD-1. | HER2/neu (erbB2) is an epidermal growth factor receptor-family member amplified/overexpressed in many adenocarcinomas and a classic target of cancer immunotherapy. SPPHPSPAFSPAFDNLYYWDQ (21-mer) from the rat HER2/neu p1209 segment is a CD4+ helper T-cell (Th) epitope presented by MHC-II (confirmed in PMC6702967). Loaded onto dendritic cells (DC) to make HER2-DC1 vaccines, it elicits antigen-specific CD4+ Th1 anti-tumor responses in rat HER2 breast-cancer models, supports CD8+ CTL activation and improves the tumor microenvironment; sequential combination with anti-PD-1 further prolongs survival of tumor-bearing rats, illustrating the cooperation of CD4+ help in checkpoint blockade. Typical uses: HER2 vaccine epitope identification, ex vivo DC loading, CD4+ T-cell proliferation/ELISPOT assays, and mechanistic studies of combined cancer immunotherapy. | HER2/neu cancer vaccine, dendritic-cell (DC) vaccine, rat breast-cancer model, CD4 Th1 immune response, combined cancer immunotherapy (anti-PD-1) | rHER2/neu p1209 epitope presented by MHC-II molecules; CD4+ T cells |
Hot Tags: cas 1443436-80-3 spphpspafspafdnlyywdq, China cas 1443436-80-3 spphpspafspafdnlyywdq manufacturers, suppliers, factory
